BIOAF (Bioasis Technologies) Selling, General, & Admin. Expense: $1.83 Mil (TTM As of Nov. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOAF Bioasis Technologies Inc BIOAF
12 GF Score
Price $0.00
View Full Analysis

What is Bioasis Technologies Selling, General, & Admin. Expense?

Bioasis Technologies BIOAF 12 Selling, General, & Admin. Expense is $1.83 Mil as of Nov. 2022. GuruFocus rates BIOAF with a GF Score™ of 12/100.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Bioasis Technologies's selling, general, & admin. expense for the three months ended in Nov. 2022 was $0.47 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Nov. 2022 was $1.83 Mil.


Bioasis Technologies  (OTCPK:BIOAF) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Bioasis Technologies Selling, General, & Admin. Expense Related Terms


Bioasis Technologies Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Bioasis Technologies's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioasis Technologies Selling, General, & Admin. Expense Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.54 3.27 2.39 1.94 1.89

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.41 0.35 0.60 0.47

BIOAF vs VRTX, REGN, SGEN: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Bioasis Technologies's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Selling, General, & Admin. Expense falls into.


BIOAF
12GF Score
Bioasis Technologies Inc BIOAF
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioasis Technologies Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $1.83 Mil mean?
Bioasis Technologies (BIOAF) has a Selling, General, & Admin. Expense of $1.83 Mil as of Nov. 2022. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Bioasis Technologies and its competitors.
Is Bioasis Technologies' Selling, General, & Admin. Expense too high?
Bioasis Technologies' current Selling, General, & Admin. Expense is $1.83 Mil. Overall, Bioasis Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioasis Technologies' Selling, General, & Admin. Expense compare to VRTX and REGN?
Bioasis Technologies' Selling, General, & Admin. Expense of $1.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Bioasis Technologies and its competitors. Bioasis Technologies's current Selling, General, & Admin. Expense is $1.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioasis Technologies stock overvalued right now?
Bioasis Technologies (BIOAF) has a current Selling, General, & Admin. Expense of $1.83 Mil. The current Selling, General, & Admin. Expense is $1.83 Mil. Bioasis Technologies' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Bioasis Technologies (BIOAF), the current Selling, General, & Admin. Expense is $1.83 Mil as of Nov. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioasis Technologies Business Description

Address 157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's xB3 program describes its proprietary carrier, p97, and components thereof, to deliver therapeutics across the blood-brain barrier (BBB).
12GF Score

Get the complete analysis for BIOAF

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price